Company news

Biophytis SA news in 2026

Biophytis SA's news releases, calls and decks from 2026, newest first.

View company

Chairman\'s Letter - General Meeting Invitation

October 21, 2026

Biophytis S A ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY

September 11, 2026

Biophytis S A to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

September 9, 2026

Biophytis S A strengthens its financial position and extends its cash runway into Q1 2027

August 31, 2026

Biophytis S A PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE

August 3, 2026

Information on annual financial statements

April 29, 2026

Biophytis S A PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE

March 13, 2026

Biophytis: LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

March 12, 2026

Biophytis S A ANNOUNCES COMPLETION OF OVER €2.0 MILLION CAPITAL INCREASE AND THE REPAYMENT OF ALL VARIABLE PRICE CONVERTIBLE DEBT

March 11, 2026

Biophytis S A increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund

February 27, 2026

Biophytis S A conclut un accord stratégique en Asie et sécurise 20 M$ pour le lancement de sa Phase 3 dans la sarcopénie

January 28, 2026

Biophytis S A enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia

January 28, 2026

Biophytis S A participe à la JP Morgan Healthcare Conference et au Biomed Forum

January 12, 2026

Biophytis S A to Participate in the JP Morgan Healthcare Conference and the Biomed Forum

January 12, 2026

Decks in 2026